Artelo Biosciences News

Express News | Artelo Biosciences Reports Publication Peer-Reviewed Article Titled "The Emerging Role of Fatty Acid Binding Protein 7 (FABP7) in Cancers,"

Moomoo 24/7Apr 23 08:37 ET

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireApr 23 08:30 ET

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireApr 22 08:30 ET

Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.

Artelo Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 2 11:53 ET

Express News | HC Wainwright & Co. Maintains Buy on Artelo Biosciences, Maintains $5 Price Target

Moomoo 24/7Apr 2 11:42 ET

Buy Rating on Artelo Biosciences: Strong Pipeline and Market Potential

TipRanksMar 26 06:45 ET

Express News | Artelo Biosciences Earlier Reported Q4 EPS $(0.99) Misses $(0.56) Estimate

Moomoo 24/7Mar 25 16:29 ET

Recap: Artelo Biosciences Q4 Earnings

Artelo Biosciences (NASDAQ:ARTL) reported its Q4 earnings results on Monday, March 25, 2024 at 08:00 AM.Here's what investors need to know about the announcement.EarningsArtelo Biosciences missed esti

BenzingaMar 25 09:20 ET

Artelo Biosciences GAAP EPS of -$3.14 Misses by $0.58

Seeking AlphaMar 25 09:05 ET

Artelo Biosciences FY23 Loss/Shr $3.14 >ARTL

Artelo Biosciences FY23 Loss/Shr $3.14 >ARTL

Dow JonesMar 25 08:02 ET

Press Release: Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update Major achievements in 2023 lay the foundation for key upcoming milestones SOLANA BEACH, Calif., March 2

Dow JonesMar 25 08:00 ET

Express News | Artelo Biosciences Has Been Granted European Patent Number EP3723752 Titled "NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF (FOR VARIOUS MEDICAL TREATMENTS)"

Moomoo 24/7Mar 20 12:06 ET

Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireMar 12 09:15 ET

Artelo Biosciences Revises Stock Options for Employee Retention

TipRanksMar 4 16:32 ET

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments

AccesswireFeb 15 09:00 ET

Top Premarket Gainers

Helius Medical Technologies (HSDT) shares were up nearly 37% premarket Tuesday after the company announced an alignment with the US Food and Drug Administration on the registrational program for strok

MT NewswiresFeb 6 07:52 ET

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireJan 23 08:30 ET

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

GlobeNewswireJan 8 08:30 ET

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted statesSOLANA BEACH, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-sta

GlobeNewswireDec 5, 2023 08:30 ET

Artelo Biosciences To Present Important New Preclinical Data On ART12.11 At The 4th Annual Med-Cannabis 2023 Conference In Germany

Artelo Biosciences To Present Important New Preclinical Data On ART12.11 At The 4th Annual Med-Cannabis 2023 Conference In Germany

BenzingaNov 30, 2023 09:01 ET